Reduction of the share capital and status of holding of own shares
(13 June 2008)
At Novo Nordisk's ordinary general meeting on 12 March 2008 it was
decided to reduce the company's B share capital from DKK 539,472,800
to DKK 526,512,800 by cancellation of part of the company's portfolio
of own B shares at a nominal value of DKK 12,960,000 divided into
12,960,000 B shares of
DKK 1.
Today, Novo Nordisk has registered the final implementation of the
reduction of the share capital with the Danish Commerce and Companies
Agency and cancelled nominally DKK 12,960,000 B shares. After the
reduction of the share capital, the company's share capital is
nominally DKK 634,000,000, which is divided into an A share capital
of nominally DKK 107,487,200 and a B share capital of nominally DKK
526,512,800.
Holding of own shares
In the company's stock exchange announcement no 33/2008 released on 9
June 2008 it was stated that Novo Nordisk A/S (NYSE: NVO) and its
wholly-owned affiliates as per 9 June 2008 owned 28,781,920 of its
own B shares of DKK 1, corresponding to a total nominal value of DKK
28,781,920 or 4.5% of the total share capital.
Since 9 June 2008 a total of 192,000 B shares have been repurchased
by Novo Nordisk A/S, and 70 B shares have been disposed of to
employees who have exercised options granted by Novo Nordisk.
Following the cancellation of nominally DKK 12,960,000 (12,960,000
shares) of the company's own B shares and pursuant to Section 28 of
the Danish Securities Trading Act, it is hereby announced that Novo
Nordisk A/S and its
wholly-owned affiliates as per 13 June 2008 own 16,013,850 of its own
B shares. This corresponds to a total nominal value of DKK 16,013,850
B shares or 2.5 % of the total share capital.
The reduction in the share capital will not affect Novo Nordisk's
share repurchase programme which will continue as previously
announced.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,300
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
Further information:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 35 / 2008